



October 9, 2024

The General Manager,
Department of Corporate Services
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai 400001

Manager – Listing Compliance
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Fandra Kurla Complex,
Bandra (E) Mumbai 400051

Dear Sir/ Madam,

Sub: Confirmation on initiation the process of obtaining No Objection Certificate from Lenders with respect to composite scheme of amalgamation amongst Sequent Scientific Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appeure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited and Sequent Research Limited under Sections 230 to 232 of the Companies Act, 2013

With reference to the above,

We hereby confirm that we have initiated the process of obtaining the No Objection Certificate from the lending scheduled commercial banks/financial institutions/debenture trustees as required under Para A (2) (k) of Part I of SEBI Master Circular dated June 20, 2023 and we shall submit the same with the Exchange before the receipt of the No-objection letter from stock exchange in terms of Regulation 37(1) of SEBI LODR.

Thanking you.

Yours sincerely,

For SeQuent Scientific Limited

Phillip Trott Company Secretary Membership Regn. No.- F-7403

Website: http://www.sequent.in | Email ld: investorrelations@sequent.in